nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—AGTR2—ACE Inhibitor Pathway—REN—adrenal gland cancer	0.196	0.197	CbGpPWpGaD
Tasosartan—AGTR2—Peptide GPCRs—GNRHR—adrenal gland cancer	0.096	0.0967	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—REN—adrenal gland cancer	0.0637	0.0642	CbGpPWpGaD
Tasosartan—AGTR2—Peptide GPCRs—TSHR—adrenal gland cancer	0.0513	0.0516	CbGpPWpGaD
Tasosartan—AGTR1—Peptide GPCRs—GNRHR—adrenal gland cancer	0.0313	0.0315	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 signaling events—TSHR—adrenal gland cancer	0.0304	0.0306	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.0303	0.0305	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 trafficking events—TSHR—adrenal gland cancer	0.024	0.0242	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—GNRHR—adrenal gland cancer	0.0231	0.0232	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.0181	0.0183	CbGpPWpGaD
Tasosartan—AGTR1—Peptide GPCRs—TSHR—adrenal gland cancer	0.0167	0.0168	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.0162	0.0163	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—GNRHR—adrenal gland cancer	0.0149	0.015	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—GNRH1—adrenal gland cancer	0.0138	0.0139	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNRHR—adrenal gland cancer	0.0133	0.0134	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.013	0.0131	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—TSHR—adrenal gland cancer	0.0123	0.0124	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GNRHR—adrenal gland cancer	0.0118	0.0119	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—GNAS—adrenal gland cancer	0.0118	0.0119	CbGpPWpGaD
Tasosartan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—adrenal gland cancer	0.0102	0.0103	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.00987	0.00994	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—POMC—adrenal gland cancer	0.00944	0.00951	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—ABCB1—adrenal gland cancer	0.00905	0.00912	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—GNRH1—adrenal gland cancer	0.00893	0.00899	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—adrenal gland cancer	0.00798	0.00804	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—POMC—adrenal gland cancer	0.00797	0.00803	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00781	0.00787	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GNRHR—adrenal gland cancer	0.00751	0.00757	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—GNAS—adrenal gland cancer	0.00716	0.00722	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00709	0.00714	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GNRHR—adrenal gland cancer	0.00699	0.00704	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00696	0.00701	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 signaling events—EGFR—adrenal gland cancer	0.00673	0.00678	CbGpPWpGaD
Tasosartan—AGTR1—Arf6 trafficking events—CTNNB1—adrenal gland cancer	0.00671	0.00676	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.0065	0.00655	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00633	0.00638	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—TSHR—adrenal gland cancer	0.00632	0.00637	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00611	0.00616	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.00591	0.00596	CbGpPWpGaD
Tasosartan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—adrenal gland cancer	0.00559	0.00563	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.00527	0.00531	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—POMC—adrenal gland cancer	0.00482	0.00486	CbGpPWpGaD
Tasosartan—Candesartan—ABCB1—adrenal gland cancer	0.00455	0.608	CrCbGaD
Tasosartan—AGTR2—Signaling by GPCR—PRKACA—adrenal gland cancer	0.00454	0.00457	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GNRH1—adrenal gland cancer	0.0045	0.00454	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00425	0.00428	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CDC42—adrenal gland cancer	0.00424	0.00427	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GNRH1—adrenal gland cancer	0.00419	0.00422	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00405	0.00408	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—TSHR—adrenal gland cancer	0.00401	0.00404	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00386	0.00389	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CDC42—adrenal gland cancer	0.00385	0.00388	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SPRY2—adrenal gland cancer	0.00383	0.00386	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TSHR—adrenal gland cancer	0.00373	0.00376	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—GNAS—adrenal gland cancer	0.00368	0.0037	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MEN1—adrenal gland cancer	0.00351	0.00354	CbGpPWpGaD
Tasosartan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—adrenal gland cancer	0.00337	0.0034	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—adrenal gland cancer	0.00321	0.00324	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—POMC—adrenal gland cancer	0.00308	0.0031	CbGpPWpGaD
Tasosartan—Losartan—ABCB1—adrenal gland cancer	0.00293	0.392	CrCbGaD
Tasosartan—AGTR2—GPCR downstream signaling—POMC—adrenal gland cancer	0.00273	0.00275	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PRKACA—adrenal gland cancer	0.00268	0.0027	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00254	0.00256	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—POMC—adrenal gland cancer	0.00248	0.00249	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—GNAS—adrenal gland cancer	0.00233	0.00235	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00231	0.00233	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GNRHR—adrenal gland cancer	0.00228	0.0023	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CDC42—adrenal gland cancer	0.00227	0.00229	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00227	0.00228	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IGF2—adrenal gland cancer	0.00219	0.00221	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—GNAS—adrenal gland cancer	0.00217	0.00219	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00212	0.00213	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IGF1R—adrenal gland cancer	0.00212	0.00213	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00206	0.00208	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—TSHR—adrenal gland cancer	0.00206	0.00207	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00199	0.00201	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TERT—adrenal gland cancer	0.00182	0.00184	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—BAD—adrenal gland cancer	0.00159	0.0016	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.00158	0.00159	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—POMC—adrenal gland cancer	0.00157	0.00158	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PRKACA—adrenal gland cancer	0.00148	0.00149	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—POMC—adrenal gland cancer	0.00146	0.00147	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—BRAF—adrenal gland cancer	0.00144	0.00145	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—EGFR—adrenal gland cancer	0.0014	0.00141	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.0014	0.00141	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CDC42—adrenal gland cancer	0.00138	0.00139	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GNRH1—adrenal gland cancer	0.00136	0.00138	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00132	0.00133	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CDC42—adrenal gland cancer	0.00125	0.00126	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SPRY2—adrenal gland cancer	0.00125	0.00126	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TSHR—adrenal gland cancer	0.00122	0.00123	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—GNAS—adrenal gland cancer	0.0012	0.00121	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MEN1—adrenal gland cancer	0.00114	0.00115	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.00113	0.00114	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CTNNB1—adrenal gland cancer	0.00104	0.00105	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—POMC—adrenal gland cancer	0.000888	0.000895	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PRKACA—adrenal gland cancer	0.000873	0.00088	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—EGFR—adrenal gland cancer	0.000827	0.000833	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—POMC—adrenal gland cancer	0.000807	0.000813	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CDC42—adrenal gland cancer	0.000741	0.000746	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF2—adrenal gland cancer	0.000714	0.000719	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—GNAS—adrenal gland cancer	0.000708	0.000713	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TP53—adrenal gland cancer	0.000694	0.000699	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF1R—adrenal gland cancer	0.00069	0.000695	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	0.000602	0.000607	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TERT—adrenal gland cancer	0.000594	0.000599	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SDHB—adrenal gland cancer	0.000539	0.000543	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—BAD—adrenal gland cancer	0.000517	0.000521	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—POMC—adrenal gland cancer	0.000476	0.00048	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—BRAF—adrenal gland cancer	0.00047	0.000474	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—EGFR—adrenal gland cancer	0.000456	0.000459	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—RRM1—adrenal gland cancer	0.000347	0.00035	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—SDHD—adrenal gland cancer	0.000347	0.00035	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CTNNB1—adrenal gland cancer	0.00034	0.000343	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—EGFR—adrenal gland cancer	0.000269	0.000271	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MED12—adrenal gland cancer	0.000259	0.000261	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TP53—adrenal gland cancer	0.000226	0.000228	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	0.000189	0.00019	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GNAS—adrenal gland cancer	0.000153	0.000154	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	0.00015	0.000151	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—POMC—adrenal gland cancer	0.000103	0.000104	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	8.22e-05	8.28e-05	CbGpPWpGaD
